-
Something wrong with this record ?
Immunophenotypic Analysis of Acute Megakaryoblastic Leukemia: A EuroFlow Study
N. Brouwer, S. Matarraz, S. Nierkens, M. Hofmans, M. Nováková, ES. da Costa, P. Fernandez, AE. Bras, FV. de Mello, E. Mejstrikova, J. Philippé, GE. Grigore, CE. Pedreira, JJM. van Dongen, A. Orfao, VHJ. van der Velden, . On Behalf Of The EuroFlow...
Language English Country Switzerland
Document type Journal Article
Grant support
E26/200.840/2021-CNE
Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
306258/2019-6
National Council for Scientific and Technological Development
NU20J-07-00028
Ministry of Health of the Czech Republic
NLK
Free Medical Journals
from 2009
PubMed Central
from 2009
Europe PubMed Central
from 2009
ProQuest Central
from 2009-01-01
Open Access Digital Library
from 2009-01-01
Open Access Digital Library
from 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2009
- Publication type
- Journal Article MeSH
Acute megakaryoblastic leukemia (AMKL) is a rare and heterogeneous subtype of acute myeloid leukemia (AML). We evaluated the immunophenotypic profile of 72 AMKL and 114 non-AMKL AML patients using the EuroFlow AML panel. Univariate and multivariate/multidimensional analyses were performed to identify most relevant markers contributing to the diagnosis of AMKL. AMKL patients were subdivided into transient abnormal myelopoiesis (TAM), myeloid leukemia associated with Down syndrome (ML-DS), AML-not otherwise specified with megakaryocytic differentiation (NOS-AMKL), and AMKL-other patients (AML patients with other WHO classification but with flowcytometric features of megakaryocytic differentiation). Flowcytometric analysis showed good discrimination between AMKL and non-AMKL patients based on differential expression of, in particular, CD42a.CD61, CD41, CD42b, HLADR, CD15 and CD13. Combining CD42a.CD61 (positive) and CD13 (negative) resulted in a sensitivity of 71% and a specificity of 99%. Within AMKL patients, TAM and ML-DS patients showed higher frequencies of immature CD34+/CD117+ leukemic cells as compared to NOS-AMKL and AMKL-Other patients. In addition, ML-DS patients showed a significantly higher expression of CD33, CD11b, CD38 and CD7 as compared to the other three subgroups, allowing for good distinction of these patients. Overall, our data show that the EuroFlow AML panel allows for straightforward diagnosis of AMKL and that ML-DS is associated with a unique immunophenotypic profile.
Cytognos SL Carretera de Madrid Km 0 Nave 9 Pol La Serna 37900 Salamanca Spain
Department of Diagnostic Sciences Ghent University C Heymanslaan 10 9000 Ghent Belgium
Institute for Laboratory Medicine Kantonsspital Aarau AG Tellstrasse 25 5001 Aarau Switzerland
Institute of Pediatrics R Bruno Lobo 50 Cidade Universitária Rio de Janeiro RJ 21941 912 Brazil
Princess Máxima Center for Pediatric Oncology Heidelberglaan 25 3584 CS Utrecht The Netherlands
Translational and Clinical Research Program Centro de Investigación del Cáncer (IBMCC
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22009755
- 003
- CZ-PrNML
- 005
- 20220425131541.0
- 007
- ta
- 008
- 220420s2022 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/cancers14061583 $2 doi
- 035 __
- $a (PubMed)35326734
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Brouwer, Nienke $u Laboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands
- 245 10
- $a Immunophenotypic Analysis of Acute Megakaryoblastic Leukemia: A EuroFlow Study / $c N. Brouwer, S. Matarraz, S. Nierkens, M. Hofmans, M. Nováková, ES. da Costa, P. Fernandez, AE. Bras, FV. de Mello, E. Mejstrikova, J. Philippé, GE. Grigore, CE. Pedreira, JJM. van Dongen, A. Orfao, VHJ. van der Velden, . On Behalf Of The EuroFlow Consortium
- 520 9_
- $a Acute megakaryoblastic leukemia (AMKL) is a rare and heterogeneous subtype of acute myeloid leukemia (AML). We evaluated the immunophenotypic profile of 72 AMKL and 114 non-AMKL AML patients using the EuroFlow AML panel. Univariate and multivariate/multidimensional analyses were performed to identify most relevant markers contributing to the diagnosis of AMKL. AMKL patients were subdivided into transient abnormal myelopoiesis (TAM), myeloid leukemia associated with Down syndrome (ML-DS), AML-not otherwise specified with megakaryocytic differentiation (NOS-AMKL), and AMKL-other patients (AML patients with other WHO classification but with flowcytometric features of megakaryocytic differentiation). Flowcytometric analysis showed good discrimination between AMKL and non-AMKL patients based on differential expression of, in particular, CD42a.CD61, CD41, CD42b, HLADR, CD15 and CD13. Combining CD42a.CD61 (positive) and CD13 (negative) resulted in a sensitivity of 71% and a specificity of 99%. Within AMKL patients, TAM and ML-DS patients showed higher frequencies of immature CD34+/CD117+ leukemic cells as compared to NOS-AMKL and AMKL-Other patients. In addition, ML-DS patients showed a significantly higher expression of CD33, CD11b, CD38 and CD7 as compared to the other three subgroups, allowing for good distinction of these patients. Overall, our data show that the EuroFlow AML panel allows for straightforward diagnosis of AMKL and that ML-DS is associated with a unique immunophenotypic profile.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Matarraz, Sergio $u Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca), Cytometry Service, NUCLEUS, Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL) Paseo de la Universidad de Coimbra s/n, Campus Miguel de Unamuno, 37007 Salamanca, Spain $u Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, Spain
- 700 1_
- $a Nierkens, Stefan $u Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, The Netherlands $1 https://orcid.org/000000033406817X
- 700 1_
- $a Hofmans, Mattias $u Department of Laboratory Medicine, Ghent University Hospital, Corneel Heymanslaan 10, 9000 Ghent, Belgium
- 700 1_
- $a Nováková, Michaela $u CLIP-Department of Pediatric Hematology and Oncology, Second Medical Faculty, Charles University and University Hospital Motol, V Uvalu 84, 15006 Prague, Czech Republic $1 https://orcid.org/0000000329645956 $7 xx0211356
- 700 1_
- $a da Costa, Elaine Sobral $u Institute of Pediatrics (IPPMG), Federal University of Rio de Janeiro (UFRJ), R. Bruno Lobo, 50-Cidade Universitária, Rio de Janeiro-RJ 21941-912, Brazil $1 https://orcid.org/0000000253405816
- 700 1_
- $a Fernandez, Paula $u Institute for Laboratory Medicine, Kantonsspital Aarau AG, Tellstrasse 25, 5001 Aarau, Switzerland
- 700 1_
- $a Bras, Anne E $u Laboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands
- 700 1_
- $a de Mello, Fabiana Vieira $u Institute of Pediatrics (IPPMG), Federal University of Rio de Janeiro (UFRJ), R. Bruno Lobo, 50-Cidade Universitária, Rio de Janeiro-RJ 21941-912, Brazil
- 700 1_
- $a Mejstrikova, Ester $u CLIP-Department of Pediatric Hematology and Oncology, Second Medical Faculty, Charles University and University Hospital Motol, V Uvalu 84, 15006 Prague, Czech Republic
- 700 1_
- $a Philippé, Jan $u Department of Diagnostic Sciences, Ghent University, C. Heymanslaan 10, 9000 Ghent, Belgium $1 https://orcid.org/0000000348575746
- 700 1_
- $a Grigore, Georgiana Emilia $u Cytognos SL, Carretera de Madrid Km. 0 Nave 9, Pol. La Serna, 37900 Salamanca, Spain
- 700 1_
- $a Pedreira, Carlos E $u Systems and Computing Department, COPPE, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro-RJ 21941-594, Brazil
- 700 1_
- $a van Dongen, Jacques J M $u Department of Immunology, Leiden University Medical Center (LUMC), Albinusdreef 2, 2333 ZA Leiden, The Netherlands $u Centro de Investigación del Cancer, Department of Medicine, University of Salamanca, 37007 Salamanca, Spain $1 https://orcid.org/0000000236507087
- 700 1_
- $a Orfao, Alberto $u Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca), Cytometry Service, NUCLEUS, Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL) Paseo de la Universidad de Coimbra s/n, Campus Miguel de Unamuno, 37007 Salamanca, Spain $u Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, Spain $1 https://orcid.org/0000000200077230
- 700 1_
- $a van der Velden, Vincent H J $u Laboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands $1 https://orcid.org/0000000194573763
- 700 1_
- $a On Behalf Of The EuroFlow Consortium,
- 773 0_
- $w MED00173178 $t Cancers $x 2072-6694 $g Roč. 14, č. 6 (2022)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35326734 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20220420 $b ABA008
- 991 __
- $a 20220425131538 $b ABA008
- 999 __
- $a ind $b bmc $g 1784384 $s 1160953
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 14 $c 6 $e 20220321 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
- GRA __
- $a E26/200.840/2021-CNE $p Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
- GRA __
- $a 306258/2019-6 $p National Council for Scientific and Technological Development
- GRA __
- $a NU20J-07-00028 $p Ministry of Health of the Czech Republic
- LZP __
- $a Pubmed-20220420
